WuXi Biologics has received FDA pre‑license inspection (PLI) approval for its MFG8 drug substance manufacturing facility in Hebei, clearing the way for commercial supply of a potential blockbuster autoimmune therapy.
The seven‑day inspection, conducted by three FDA inspectors, reviewed the site’s quality management systems and drug substance manufacturing operations. The successful outcome strengthens WuXi Biologics’ regulatory track record and confirms the facility’s compliance with current good manufacturing practice requirements for large‑scale biologics production.
MFG8 is part of WuXi Biologics’ global manufacturing network and is equipped with twelve 4,000‑liter single‑use bioreactors. The facility is designed around a “scale‑out” strategy that allows flexible commercial manufacturing at volumes ranging from 4,000 to 20,000 liters, supporting different product and demand profiles.
In addition to capacity, the site incorporates sustainability features, including digital process platforms and a rooftop photovoltaic system to support carbon reduction, resource reuse, and recycling initiatives.